[Level of circulating Alarin in obese children and its association with insulin resistance]

Man-Qin Li1, Jiao-Yang Li, Li Xie

  • 1Pediatric Intensive Care Unit, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China. 7988780@qq.com.

Insights

Obese children show elevated circulating Alarin levels, which correlate with increased body mass index (BMI) and insulin resistance (IR). This suggests Alarin may play a role in the development of childhood obesity and metabolic dysfunction.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Research
  • Obesity Studies

Background:

  • Childhood obesity is a growing global health concern.
  • Obesity is frequently associated with metabolic complications, including insulin resistance (IR).
  • Identifying biomarkers for obesity and associated metabolic disturbances is crucial for early intervention.

Purpose of the Study:

  • To investigate the levels of circulating Alarin in obese children.
  • To explore the association between Alarin levels and various metabolic parameters in this population.

Main Methods:

  • A case-control study involving 86 obese children and 82 healthy controls.
  • Measurement of anthropometric data, blood pressure, and metabolic markers (lipids, glucose, insulin).
  • Calculation of indices for insulin resistance (HOMA-IR, WBISI) and assessment of circulating Alarin via ELISA.

Main Results:

  • Obese children exhibited significantly higher circulating Alarin levels compared to healthy controls.
  • Alarin levels were also elevated in obese children with IR compared to those without IR.
  • Circulating Alarin positively correlated with BMI, triglycerides, fasting glucose, and IR markers, and negatively with insulin sensitivity.

Conclusions:

  • Circulating Alarin levels are significantly increased in obese children.
  • Elevated Alarin may be linked to the pathogenesis of obesity and the development of insulin resistance in children.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
210
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
631
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
144
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
184